{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["datopotamab deruxtecan"]],"indication":"advanced solid tumors","name":"TROPION-PanTumor02","nct_id":"NCT05460273","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropion-pantumor02-nct05460273. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"This single-arm study consists of multiple cohorts, divided by indication.","label":"Dato-DXd Arm","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung","Triple Negative Breast Cancer"],"enrollment":{"count":119,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Datopotamab Deruxtecan (Dato-DXd)","otherNames":["DS-1062a"],"type":"DRUG"}],"last_update":"2026-08-31","lead_sponsor":"AstraZeneca","official_title":"Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2023-11-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up."}],"references":[],"start_date":{"date":"2022-07-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","url":"https://clinicaltrials.gov/study/NCT05460273"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropion-pantumor02-nct05460273"}